Clinical Trial

United States Pharmacovigilance Market Research Report 2023: Demand Soars for Pharmacovigilance in Response to Escalating Adverse Drug Reactions – Forecasts to 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "United States Pharmacovigilance Market, By Region, Competition Forecast and Opportunities, 2018-2028F" report has been added to ResearchAndMarkets.com's offering.…

5 days ago

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March…

5 days ago

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity…

5 days ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE…

5 days ago

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based…

5 days ago

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

New Program Targets Estimated $2.5 Billion Eye Pain MarketFREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”,…

5 days ago

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC’s 23M AiBtl Share Ownership as Hundred Million Dollars

FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire  – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical…

5 days ago

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to…

5 days ago

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Achieves critical first step toward priority review voucherBASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq:…

5 days ago